Cooperate clinical trial

Japanese randomized controlled trial. Designed to test maximum dose: 1) ACE inhibitor 2) angiotensin 2 receptor antagonist (ARB) 3) 1 & 2 (combined therapy) in non-diabetic renal disease. 263 patients serum creatinine 1.5-4.5 mg/dL glomerular filtration rate 20-70 mL/min/m2 Most patients had treated hypertension. Mean blood pressure 130/75 on therapy other than ACE inhibitor or ARB Mean follow-up: 2.9 years Combined endpoints: 1) doubling of serum creatinine, or 2) end stage renal disease (ESRD) Results: 1) end point lowest in combined therapy group (11%) 2) 23% in ACE inhibitor or ARB alone 3) other associations with lower incidence of endpoint a) larger reductions in proteinuria b) use of diuretic 4) similar reductions in blood pressure (BP) in 3 groups 5 mm systolic BP; 3 mm diastolic BP 5) no difference in adverse effects

General

clinical trial hypertension clinical trials

References

Journal Watch 23(5):37, 2003 Nakao N et al, Lancet 361:117,2003